Keyphrases
Valproate
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Lymphoma Patients
100%
CD20
50%
Histone Deacetylase Inhibitor (HDACi)
30%
Anticonvulsive
20%
Rituximab
20%
Epigenetic Modification
20%
R-CHOP
20%
Chemotherapy
10%
FACS Analysis
10%
Acetylation
10%
Chemotherapy Regimen
10%
PCR Analysis
10%
Phase I Clinical Trial
10%
Code Changes
10%
Cell Surface
10%
Lymphoma Cells
10%
H3K9ac
10%
Prednisone
10%
Cyclophosphamide
10%
Anti-CD20 Antibody
10%
Most Common Form
10%
First-line Therapy
10%
B-cell Lymphoma
10%
Epigenetic Code
10%
Lymphoma
10%
New Therapies
10%
Oral Dose
10%
Lymphoid Malignancies
10%
Peripheral Blood Mononuclear Cells
10%
Doxorubicin
10%
Medicine and Dentistry
Sodium Valproate
100%
CD20
100%
Diffuse Large B-Cell Lymphoma
100%
Rituximab
30%
Epigenetic Modification
20%
CHOP
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Histone Deacetylase Inhibitor
20%
Upregulation
20%
Doxorubicin
10%
Fluorescence Activated Cell Sorting
10%
Cell Surface
10%
Vincristine
10%
Lymphoma Cell Line
10%
B-Cell Lymphoma
10%
Acetylation
10%
Lymphoma
10%
Chemotherapy
10%
Biopsy Technique
10%
Messenger RNA
10%
Clinical Trial
10%
Prednisone
10%
Real-Time Polymerase Chain Reaction
10%
Cyclophosphamide
10%
In Vitro
10%
Peripheral Blood Mononuclear Cell
10%
Immunology and Microbiology
CD20
100%
B Cell
100%
Rituximab
42%
Epigenetic Modification
28%
Upregulation
28%
Histone
28%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
28%
Lymphoma Cell Line
14%
Acetylation
14%
Cyclophosphamide
14%
Fluorescence Activated Cell Sorting
14%
Peripheral Blood Mononuclear Cell
14%
Prednisone
14%
Cell Surface
14%
Real-Time Polymerase Chain Reaction
14%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Valproate
100%
Diffuse Large B Cell Lymphoma
100%
Rituximab
30%
Histone Deacetylase Inhibitor
20%
Chemotherapy
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Lymphoma
10%
Prednisone
10%
Fluorescence Activated Cell Sorting
10%
Doxorubicin
10%
Cyclophosphamide
10%
Messenger RNA
10%
Clinical Trial
10%
B Cell Lymphoma
10%
Vincristine
10%